Journal: BMC Complementary and Alternative Medicine

Article Title: Supercritical fluid extract of Lycium chinense Miller root inhibition of melanin production and its potential mechanisms of action

doi: 10.1186/1472-6882-14-208

Figure Lengend Snippet: The effects of Lycium chinense Miller root SFE on melanin content in PD98059, SB 203580-, SP600125- and IBMX-treated B16F10 cells. The results are presented as percentages of the control values, and the data are presented as the mean ± S.D. of three separate experiments. The values are significantly different compared with the control. * p < 0.05.

Article Snippet: Protein kinase regulators, including3-isobutyl-1-methyl-xanthine (IBMX), SB203580 (p38 MAPK-inhibitor), SP600125 (c-Jun N-terminal kinase inhibitor; JNK inhibitor) and PD98059 (MEK 1/2-inhibitor), were obtained from Tocris (Ellisville, Missouri, USA).

Techniques: Control

Journal: Oncotarget

Article Title: Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells

doi: 10.18632/oncotarget.20249

Figure Lengend Snippet: (A) , (B) Shp2 knockdown decreased the proliferation of H1975 cells (A) and H292 cells (B). Lung cancer cells were transfected with Shp2 or control siRNA for 72 h in RPMI 1640 medium containing 0.5% FBS. Cell proliferation was measured using the CCK8 assay at 72 h after transfection, and the results are expressed as means ± SD (N = 4); * P < 0.05 versus control. (C) , (D) Shp2 knockdown enhanced gefitinib sensitivity in NSCLC cells. (E) , (F) Shp2 overexpression decreased gefitinib sensitivity in NSCLC cells. H1975 and H292 cells transfected with Shp2/control siRNAs or Shp2 WT /vector were treated with 0–10 μM gefitinib for 3 days, and then cell proliferation was measured using the CCK8 assay. The cell-viability percentage was calculated by adjusting the DMSO control group to 100%. Points and error bars represent the mean and SD values from 3 independent experiments. Black points: control siRNAs/vector; Gray points: Shp2-siRNAs/Shp2 WT .

Article Snippet: The ERK1/2 pharmacological inhibitor U0126 was purchased from Calbiochem (Merck, Darmstadt, Germany) and the EGFR-TKIs gefitinib (Iressa) was from Tocris Bioscience (Bristol, UK).

Techniques: Knockdown, Transfection, Control, CCK-8 Assay, Over Expression, Plasmid Preparation

Journal: Oncotarget

Article Title: Shp2 regulates migratory behavior and response to EGFR-TKIs through ERK1/2 pathway activation in non-small cell lung cancer cells

doi: 10.18632/oncotarget.20249

Figure Lengend Snippet: (A) Comparison of gefitinib sensitivity of H292 cells transfected with vector or Shp2 WT and treated with DMSO or U0126; cell survival was measured using the CCK8 assay. (B) U0126 treatment abrogated Shp2 WT -induced upregulation of c-Myc and fibronectin expression and downregulation of E-cadherin expression in H292 cells. Equal amounts of lysates from cells transfected with vector/Shp2 WT were immunoblotted with the indicated antibodies. (C) , (D) U0126 inhibits H292 cell migration; cells treated with DMSO or U0126 were used in wound-healing assays (C) and Transwell-migration assays (D). * P < 0.05 versus controls.

Article Snippet: The ERK1/2 pharmacological inhibitor U0126 was purchased from Calbiochem (Merck, Darmstadt, Germany) and the EGFR-TKIs gefitinib (Iressa) was from Tocris Bioscience (Bristol, UK).

Techniques: Comparison, Transfection, Plasmid Preparation, CCK-8 Assay, Expressing, Migration

Journal: International Journal of Medical Sciences

Article Title: 17β-Estradiol Inhibits Mesenchymal Stem Cells-Induced Human AGS Gastric Cancer Cell Mobility via Suppression of CCL5- Src/Cas/Paxillin Signaling Pathway

doi: 10.7150/ijms.6851

Figure Lengend Snippet: CCL-5 induces AGS cell mobility via Src signaling pathway. (A) AGS cells were pretreated with vehicle, LY294002 (Akt activation inhibitor, 1μM), U0126 (ERK1/2 activation inhibitor, 1μM), SB203580 (p38 MAPK inhibitor, 1μM), SP600125 (JNK1/2 inhibitor, 1μM) or PP2 (Src inhibitor, 1μM) for 1h, and followed by recombinant CCL-5 (10 ng/ml) administration for 24h. (B) AGS cells were treated with these inhibitors, respectively. AGS cells were harvested and measured for cellular mobility capacity. **, p <0.01 versus control (line 1); ##, p <0.01 versus CCL-5 treatment (line 2) (mean ± SD, n = 3).

Article Snippet: The LY294002 (PI3K inhibitor), U0126 (MEK1/2 inhibitor), SB203680 (p38 MAPK inhibitor), SP600125 (JNK inhibitor), and PP2 (Src inhibitor) were purchased from TOCRIS (Ellisville, Missouri, USA).

Techniques: Activation Assay, Recombinant, Control

Journal: Hypertension

Article Title: Mitogen-Activated Protein Kinases Mediate Upregulation of Hypothalamic Angiotensin II Type 1 Receptors in Heart Failure Rats

doi: 10.1161/hypertensionaha.108.113639

Figure Lengend Snippet: Figure 5. Immunohistochemical analysis of AT1-R immunoreactivity in the PVN of VEH-treated Sham rats and HF rats treated for 4 weeks with ICV VEH, losartan, PD98059, SP600125, or SB203580. A, Representative sections of PVN from animals undergoing each treatment protocol. Third ventricle is to the right. B, Grouped data showing numbers of AT1-R–positive neurons counted in PVN-dp, PVN-mp, PVN-vlp, and PVN-pm. Values are expressed as meansSEM (n6 to 7 for each group). *P0.05 compared with ShamVEH; †P0.05 HFtreatment compared with HFVEH. ‡P0.05, PVN-mp compared with other PVN regions, ShamVEH.

Article Snippet: The selective p44/42 MAPK inhibitor PD98059, the JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 were obtained from Tocris (Ellisville, MO).

Techniques: Immunohistochemical staining

Journal: Hypertension

Article Title: Mitogen-Activated Protein Kinases Mediate Upregulation of Hypothalamic Angiotensin II Type 1 Receptors in Heart Failure Rats

doi: 10.1161/hypertensionaha.108.113639

Figure Lengend Snippet: Figure 6. Immunohistochemical analysis of AT1-R immunoreactivity in the SFO of VEH-treated Sham rats and HF rats treated for 4 weeks with ICV VEH, losartan, PD98059, SP600125, or SB203580. A, Representative sections of SFO from animals undergoing each treatment protocol. Third ventricle is at bottom of each image. B, Grouped data showing numbers of AT1-R positive neurons counted in central SFO. Values are expressed as meansSEM (n6 to 7 for each group). *P0.05 compared with ShamVEH; †P0.05 HFtreatment compared with HFVEH.

Article Snippet: The selective p44/42 MAPK inhibitor PD98059, the JNK inhibitor SP600125 and the p38 MAPK inhibitor SB203580 were obtained from Tocris (Ellisville, MO).

Techniques: Immunohistochemical staining